We investigated antigenic features associated with different tumor progression steps in primary melanoma, interpreted as different patterns of growth (radial and vertical) in the same and in different lesions. Thirty-eight primary melanomas were examined: 18 superficial spreading malanomas, 13 superficial spreading melanomas with a nodular area and 7 nodular melanomas. 225.28,763.74, CL.203, VF19LL209, VF19LL217, Q5.13, W6.32 and anti-HLA-DR monoclonal antibodies were used. Phenotypic differences between radial and vertical growth areas were observed but no statistical significance could be found.
Get full access to this article
View all access options for this article.
References
1.
BalabanG., HerlynM., GuerryD. I.V., BartoloR., KoprowskiH., ClarkW.H., NowellP.C.: Cytogenetics of human malignant melanoma and pre-malignant lesions. Cancer Genet. Cytogenet., 11(4): 429–439, 1984.
2.
BrockerE.B., SuterL., SorgC.: HLA-DR antigen expression in primary melanomas of the skin. J. Invest. Dermatol., 82: 244–247, 1984.
3.
ClarkW.H., ElderD.E., GuerryD., EpsteinM.N., GreeneM.H., Van HornM.: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 15: 1147–1165, 1984.
4.
ClarkW.H., ElderD.E., Van HornM.: The biologic forms of malignant melanoma. Hum. Pathol., 17: 443–450, 1986.
5.
ElderD.E., GuerryD. I.V., EpsteinM.N., ZehengebotL., LuskE., Van HornM., ClarkW.H.Jr.: Invasive malignant melanomas lacking competence for metastasis. Am. J. Der-matopathol., 6 (suppl. 1): 55–61, 1984.
6.
GarriguesH.J., TilgenW., HellstromI., FrankeW., HellstromK.E.: Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int. J. Cancer, 29: 511–515, 1982.
7.
HerlynM., BalabanG., BennicelliJ., Du PontG. I.V., HalabanR., HerlynD., ElderD.E., MaulG.G., SteplewskiZ., NowellP.C., ClarkW.H., KoprowskiH.: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J. Natl. Cancer Inst., 74: 283–289, 1985.
8.
HerlynM., ThurinJ., BalabanG., BennicelliJ.L., HerlynD., ElderD.E., BondiE., GuerryD., NowellP.C., ClarkW.H., KoprowskiH.: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res., 45: 5670–5676, 1985.
9.
HolzmanB., BrockerE.B., LehmanJ.M., RuiterD.J., SorgG., ReithmullerG., JohnsonJ.P.: Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int. J. Cancer, 39: 466–471, 1987.
10.
NataliP.G., CavaliereR., BigottiA., NicotraM.R., RussoC., NgA.N., GiacominiP., FerroneS.: Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J. Immunol., 130: 1462–1466, 1983.
11.
RuiterD.J., BergmanW., VelvaartK., SchefferE., van VlotenW.A., RussoC., FerroneS.: Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res., 44: 3930–3935, 1984.
12.
SuterL., BruggenJ., BrockerE.B., SorgC.: A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int. J. Cancer, 35: 787–791, 1985.
